Among these, a class of medications developed for the treatment of type 2 diabetes (T2D) known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offers promise through strong epidemiological and preclinical data suggesting neuroprotective effects. Here, GLP1R is linked to type 2 diabetes mellitus.